US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Polaryx Therapeutics Inc

2.07

-0.0700-3.27%

Post-market: 2.070.00000.00%19:53 EDT

Volume:108.47K

Turnover:222.69K

Market Cap:103.18M

PE:-15.11

High:2.15

Open:2.14

Low:2.03

Close:2.14

52wk High:48.91

52wk Low:1.86

Shares:49.85M

Float Shares:6.78M

Volume Ratio:0.79

T/O Rate:1.60%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1370

EPS(LYR):-0.1978

ROE:-96.56%

ROA:-42.52%

PB:9.43

PE(LYR):-10.46

Loading ...

Overview Company News Filings

Polaryx initiated with a Strong Buy at Raymond James

We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth

Simply Wall St.

Polaryx Net Loss Narrows 36.9% to $1.38 Million in Q2 FY26; Operating Loss Widens 56.1% to $1.38 Million

Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX)

Raymond James Initiates Polaryx Therapeutics at Strong Buy

MT Newswires Live

Polaryx Therapeutics Price Target Announced at $6.00/Share by Raymond James

Polaryx Therapeutics Announces Annual Shareholder Meeting

Polaryx Therapeutics Initiated at Buy by LUCID Capital Markets

Polaryx Therapeutics Announces Chief Medical Officer Resignation

Polaryx Therapeutics CMO Lisa Bollinger Resigns Effective Immediately

Polaryx Therapeutics Sets 2026 Annual Shareholder Meeting as Virtual Event

Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co.

Polaryx initiated with a Buy at H.C. Wainwright

Polaryx Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $7

THOMSON REUTERS

Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase

BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing

Polaryx Therapeutics closes USD 10 million PIPE offering of 2,502,696 shares at USD 4 each

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of Soteria Phase 2 Basket Trial

THOMSON REUTERS

Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial

Polaryx net loss narrows to $2.54 million in Q1 FY26

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/PLYX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"PLYX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","market":"US","secType":"STK","nameCN":"Polaryx Therapeutics Inc","latestPrice":2.07,"timestamp":1787342400000,"preClose":2.14,"halted":0,"volume":108472,"hourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:53 EDT","volume":64,"amount":132.5006,"timestamp":1787356396629,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.032710280373831904,"floatShares":6777800,"shares":49846000,"eps":-0.137,"marketStatus":"Market Closed","change":-0.07,"latestTime":"08-21 16:00:00 EDT","open":2.14,"high":2.15,"low":2.03,"amount":222692.690584,"amplitude":0.056075,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.137,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1769749200000,"exchange":"NASDAQ","adjPreClose":2.14,"preHourTrading":{"tag":"盘前","latestPrice":2.01,"preClose":2.14,"latestTime":"09:28 EDT","volume":12117,"amount":24449.735914800003,"timestamp":1787318913067,"change":-0.13,"changeRate":-0.060748,"amplitude":0.11215},"postHourTrading":{"tag":"盘后","latestPrice":2.07,"preClose":2.07,"latestTime":"19:53 EDT","volume":64,"amount":132.5006,"timestamp":1787356396629,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7916797426893581},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PLYX\",,,,,undefined,":{"symbol":"PLYX","floatShares":6777800,"roa":"-42.52%","roe":"-96.56%","lyrEps":-0.197809,"volumeRatio":0.7916797426893581,"shares":49846000,"dividePrice":0,"high":2.15,"amplitude":0.056075,"preClose":2.14,"low":2.03,"week52Low":1.86,"pbRate":"9.43","week52High":48.91,"institutionHeld":0,"latestPrice":2.07,"eps":-0.137,"divideRate":0,"volume":108472,"delay":0,"ttmEps":-0.137,"open":2.14,"prevYearClose":45,"prevWeekClose":2.6,"prevMonthClose":2.31,"prevQuarterClose":2.66,"fiveDayClose":2.6,"twentyDayClose":2.05,"sixtyDayClose":2.51},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PLYX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"PLYX","fiscalQuarterEnding":"2026/06","expectedEps":-0.05,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PLYX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PLYX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":4,"updateTime":1786680000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/PLYX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"PLYX","date":"2026-08-21","current":-15.109489,"percent":0.913669,"low":-201.755192,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"high":-13.892286,"avg":-26.119255,"sd":21.979805,"marketCap":106670425},"quantilePoints":[{"date":"2026-01-30","current":-58.797227,"twenty":-58.797227,"median":-58.797227,"eighty":-58.797227,"marketCap":482901629},{"date":"2026-02-06","current":-92.230945,"twenty":-129.699766,"median":-109.380137,"eighty":-58.797227,"marketCap":757492752},{"date":"2026-02-13","current":-16.832147,"twenty":-126.529328,"median":-58.797227,"eighty":-25.939953,"marketCap":138242427},{"date":"2026-02-20","current":-15.391039,"twenty":-99.090622,"median":-34.183094,"eighty":-16.79756,"marketCap":126406602},{"date":"2026-02-27","current":-18.388545,"twenty":-65.483971,"median":-21.847205,"eighty":-15.852193,"marketCap":151025117},{"date":"2026-03-06","current":-15.102817,"twenty":-58.797227,"median":-17.581524,"eighty":-15.852193,"marketCap":124039438},{"date":"2026-03-13","current":-26.804618,"twenty":-52.848332,"median":-19.339676,"eighty":-15.932895,"marketCap":220146331},{"date":"2026-03-20","current":-32.569052,"twenty":-39.601662,"median":-22.827159,"eighty":-16.059713,"marketCap":267489628},{"date":"2026-03-27","current":-33.617166,"twenty":-34.863297,"median":-29.312147,"eighty":-16.128886,"marketCap":302050234},{"date":"2026-04-02","current":-40.045527,"twenty":-39.919067,"median":-31.906143,"eighty":-16.140415,"marketCap":359809057},{"date":"2026-04-10","current":-30.350294,"twenty":-38.506935,"median":-31.819676,"eighty":-16.417108,"marketCap":272697390},{"date":"2026-04-17","current":-33.669857,"twenty":-37.045768,"median":-31.906143,"eighty":-16.636156,"marketCap":302523667},{"date":"2026-04-24","current":-28.031869,"twenty":-35.562162,"median":-31.819676,"eighty":-16.762974,"marketCap":251866340},{"date":"2026-05-01","current":-27.663028,"twenty":-34.579831,"median":-30.218565,"eighty":-17.281773,"marketCap":248552309},{"date":"2026-05-08","current":-20.128146,"twenty":-34.275325,"median":-29.928762,"eighty":-18.065737,"marketCap":180851394},{"date":"2026-05-15","current":-17.967795,"twenty":-34.128071,"median":-28.532438,"eighty":-17.67102,"marketCap":161440642},{"date":"2026-05-22","current":-28.799226,"twenty":-34.059774,"median":-27.768411,"eighty":-17.809721,"marketCap":186532590},{"date":"2026-05-29","current":-22.293817,"twenty":-33.996545,"median":-27.504954,"eighty":-17.904565,"marketCap":144397055},{"date":"2026-06-05","current":-18.492904,"twenty":-33.827932,"median":-26.891329,"eighty":-18.119363,"marketCap":119778541},{"date":"2026-06-12","current":-17.396487,"twenty":-33.648781,"median":-26.314014,"eighty":-17.641188,"marketCap":112677046},{"date":"2026-06-18","current":-16.884826,"twenty":-33.534361,"median":-25.713443,"eighty":-17.290923,"marketCap":109363016},{"date":"2026-06-26","current":-16.884826,"twenty":-33.180562,"median":-24.313934,"eighty":-17.139848,"marketCap":109363016},{"date":"2026-07-02","current":-18.858377,"twenty":-33.090251,"median":-23.364528,"eighty":-17.282806,"marketCap":122145706},{"date":"2026-07-10","current":-17.761959,"twenty":-32.741985,"median":-22.293817,"eighty":-17.323392,"marketCap":115044211},{"date":"2026-07-17","current":-16.884826,"twenty":-32.569052,"median":-20.503003,"eighty":-17.031015,"marketCap":109363016},{"date":"2026-07-24","current":-15.422936,"twenty":-32.510645,"median":-20.174077,"eighty":-16.884826,"marketCap":99894356},{"date":"2026-07-31","current":-15.715314,"twenty":-32.46514,"median":-20.022763,"eighty":-16.813445,"marketCap":101788088},{"date":"2026-08-07","current":-16.226975,"twenty":-32.288502,"median":-19.406585,"eighty":-16.664276,"marketCap":105102119},{"date":"2026-08-14","current":-18.273621,"twenty":-31.997409,"median":-19.285083,"eighty":-16.519353,"marketCap":118358242},{"date":"2026-08-21","current":-15.574598,"twenty":-31.888849,"median":-18.858377,"eighty":-16.490115,"marketCap":106670425}],"updateTime":1787461618351},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"PLYX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660448334","title":"Polaryx initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2660448334","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660448334?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:19","pubTimestamp":1786954798,"startTime":"0","endTime":"0","summary":"Raymond James initiated coverage of Polaryx (PLYX) with a Strong Buy rating and $6 price target Polaryx is advancing PLX-200 into a Phase 2 basket ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-strong-buy-at-raymond-james-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LU1363072403.SGD","LU2265009873.SGD","LU0971096721.USD","BK4127","BK4007","IE00B3QW5Z07.USD","RJF","PLYX","IE00BGHQF748.EUR","BK4588","IE00B64PRP62.GBP","LU1804176565.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177697","title":"We Think Polaryx Therapeutics (NASDAQ:PLYX) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177697","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177697?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:22","pubTimestamp":1786886555,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-plyx/polaryx-therapeutics/news/we-think-polaryx-therapeutics-nasdaqplyx-can-afford-to-drive","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-plyx/polaryx-therapeutics/news/we-think-polaryx-therapeutics-nasdaqplyx-can-afford-to-drive","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["QQQ","NDX","QQQJ","BK4007","IYW","GPIQ","MNQmain","PLYX",".IXIC","QQQE","PSQ","QLD","QID","NQmain","FTEC","QDTE","QQQY","TQQY","JEPQ","NVIW.SI","ONEQ","QQQM","QYLG","TECS","SQQQ","TQQQ","QQQA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659672441","title":"Polaryx Net Loss Narrows 36.9% to $1.38 Million in Q2 FY26; Operating Loss Widens 56.1% to $1.38 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659672441","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659672441?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:34","pubTimestamp":1786653290,"startTime":"0","endTime":"0","summary":"Polaryx net loss narrows 36.9% to $1.38 million in Q2 FY26; operating loss widens 56.1% to $1.38 millionPolaryx posted a GAAP net loss of USD 1.38 million for the quarter ended June 30, 2026, widening","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL1ZsJ2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659423166","title":"Analysts Offer Insights on NA Companies: SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659423166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659423166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:10","pubTimestamp":1786637416,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on SpaceX (SPCX) and Polaryx Therapeutics, Inc. (PLYX) with bul...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spacex-spcx-and-polaryx-therapeutics-inc-plyx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-spacex-spcx-and-polaryx-therapeutics-inc-plyx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4089","LU1861559042.SGD","LU1861558580.USD","SPCX","SPAX","SPCF","LU2360107168.USD","WARP","SNK","SPCG","PLYX","ELOL","LOFF","SPAL","UFO","SSPC","ORBX","BK4007","SPCM","XOVR","SPCU","BK4141","WSPC","MARS","DXYZ","BK4615","NA","SPCH","LU2290526834.HKD","LOFD","LU1861215975.USD","SPCQ","LU1861220033.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659156211","title":"Raymond James Initiates Polaryx Therapeutics at Strong Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2659156211","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659156211?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:14","pubTimestamp":1786619675,"startTime":"0","endTime":"0","summary":"Raymond James Initiates Polaryx Therapeutics at Strong Buy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4127","IE00BGHQF748.EUR","LU0971096721.USD","BK4585","LU1804176565.USD","LU2265009873.SGD","IE00B3QW5Z07.USD","PLYX","BK4007","LU1363072403.SGD","RJF","IE00B64PRP62.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659669155","title":"Polaryx Therapeutics Price Target Announced at $6.00/Share by Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2659669155","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659669155?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:43","pubTimestamp":1786617780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PLYX/analyst-ratings","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RJF","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655336138","title":"Polaryx Therapeutics Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2655336138","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655336138?lang=en_us&edition=fundamental","pubTime":"2026-07-29 05:01","pubTimestamp":1785272491,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics announces annual shareholder meetingPolaryx Therapeutics schedules its annual shareholder meeting for Sept. 10, 2026, to be held virtually via live webcast.Shareholders will vote ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260728:nNDL3jQpfl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654017029","title":"Polaryx Therapeutics Initiated at Buy by LUCID Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2654017029","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654017029?lang=en_us&edition=fundamental","pubTime":"2026-07-27 20:14","pubTimestamp":1785154440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PLYX/analyst-ratings(END) Dow Jones NewswiresJuly 27, 2026 08:14 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653785255","title":"Polaryx Therapeutics Announces Chief Medical Officer Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2653785255","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653785255?lang=en_us&edition=fundamental","pubTime":"2026-07-22 05:08","pubTimestamp":1784668096,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics, Inc. ( ($PLYX) ) just unveiled an announcement. On July 19, 2026, Polaryx Therapeutics, Inc. announced the immediate resignat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/polaryx-therapeutics-announces-chief-medical-officer-resignation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/polaryx-therapeutics-announces-chief-medical-officer-resignation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653783116","title":"Polaryx Therapeutics CMO Lisa Bollinger Resigns Effective Immediately","url":"https://stock-news.laohu8.com/highlight/detail?id=2653783116","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653783116?lang=en_us&edition=fundamental","pubTime":"2026-07-22 04:36","pubTimestamp":1784666166,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics CMO Lisa Bollinger resigns effective immediatelyPolaryx Therapeutics Chief Medical Officer Lisa Bollinger resigned effective immediately on July 19, 2026.Clinical timelines, regul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260721:nNDL1kyWS6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652288665","title":"Polaryx Therapeutics Sets 2026 Annual Shareholder Meeting as Virtual Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2652288665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652288665?lang=en_us&edition=fundamental","pubTime":"2026-07-17 20:02","pubTimestamp":1784289725,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics sets 2026 annual shareholder meeting as virtual eventPolaryx Therapeutics set its 2026 annual stockholders meeting for Sept. 10, 2026, held virtually.Investors on record as of Jul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nNDL5sHVRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650923219","title":"Polaryx Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2650923219","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650923219?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:19","pubTimestamp":1783592340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PLYX/analyst-ratings(END) Dow Jones NewswiresJuly 09, 2026 06:19 ET","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650192373","title":"Polaryx initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2650192373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650192373?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:15","pubTimestamp":1783592108,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Polaryx (PLYX) with a Buy rating and $7 price target PLX-200 uses a long-approved ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/polaryx-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650892804","title":"Polaryx Therapeutics, Inc. : H.c. Wainwright Initiates Coverage with Buy Rating and Target Price $7","url":"https://stock-news.laohu8.com/highlight/detail?id=2650892804","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650892804?lang=en_us&edition=fundamental","pubTime":"2026-07-09 18:01","pubTimestamp":1783591308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260709:nAZN4T6UW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639161213","title":"Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2639161213","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639161213?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:01","pubTimestamp":1780012880,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics disclosed an increase in beneficial ownership tied to Mstone Partners Healthcare, which bought 88,453 common shares at USD 4.07.Alex Keun Mo Yang, chief executive officer, was listed as an indirect beneficial owner through Mstone Partners Healthcare.The filing showed 24,233,249 common shares beneficially owned following the purchase.The transaction value was USD 360,000 in gross proceeds to the issuer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDL64dvV1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Mstone Partners Healthcare reports USD 360,000 Polaryx Therapeutics common share purchase","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693779","title":"BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693779","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693779?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:37","pubTimestamp":1779971824,"startTime":"0","endTime":"0","summary":"BRIEF-Polaryx Therapeutics Closes $10 Million Private Placement Equity FinancingMay 28 (Reuters) - Polaryx Therapeutics, Inc PLYX.O:ANNOUNCES CLOSING OF $10 MILLION PRIVATE PLACEMENT EQUITY FINANCING ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nFWN425108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLYX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693477","title":"Polaryx Therapeutics closes USD 10 million PIPE offering of 2,502,696 shares at USD 4 each","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693477","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693477?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:31","pubTimestamp":1779971496,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics closed a $10 million PIPE on May 28, 2026 through an unregistered sale of common stock.Investors bought 2,502,696 shares at an average price of about $4 per share.Proceeds earmarked for the Phase 2 SOTERIA basket trial of PLX-200, ongoing R&D, working capital, general corporate purposes.Financing expected to extend operating runway into the second quarter of 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLbfzWjj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4112","PLYX","IE00BKPKM429.USD","IE00BN0W2W23.USD","SG9999014005.SGD","BK4585","BK4588","IE00B64PRP62.GBP","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","LU2210149790.SGD","BK4007","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","LU2095319765.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469313","title":"Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of Soteria Phase 2 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469313","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469313?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971402,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA64Y6TY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638693224","title":"Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638693224","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638693224?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:30","pubTimestamp":1779971400,"startTime":"0","endTime":"0","summary":"PARAMUS, NJ, May  28, 2026  (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (the “Company” or “Polaryx”) (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying thera","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302836/0/en/Polaryx-Therapeutics-Announces-Closing-of-10-Million-Private-Placement-Equity-Financing-to-Support-Launch-of-SOTERIA-Phase-2-Basket-Trial.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","PLYX","EQR","BK4215","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635808870","title":"Polaryx net loss narrows to $2.54 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635808870","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635808870?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:13","pubTimestamp":1778840018,"startTime":"0","endTime":"0","summary":"Polaryx Therapeutics reported a net loss of $2.54 million for the three months ended March 31, 2026, narrowing from a $5.05 million loss a year earlier.Operating loss narrowed to $1.96 million from $5.05 million, as operating expenses fell to $1.96 million from $5.05 million.Research and development expense dropped to $679,000 from $4.72 million, while general and administrative expense climbed to $1.28 million from $336,000.Other expense related to direct listing offering costs was $586,000 versus none a year earlier; cash and cash equivalents totaled $3.08 million at quarter-end.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Polaryx Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL4pLD28:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}]}}